Overview
Edison’s target markets are mitochondrial diseases where CoQ10 or CoQ10 analogs have demonstrated evidence of efficacy, but where the response was suboptimal. Edison has segmented this market into two categories– adults with classic neurodegenerative diseases of aging such as Huntington’s and Parkinson’s disease, and children with inherited mitochondrial diseases.
